The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma.

abstract：:Novel therapies, particularly those that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), have improved the treatment of advanced non-small-cell lung cancer (NSCLC). The search continues for biomarkers that can predict which patients are most likely to benefit from these th...

journal_title：Clinical lung cancer

authors： Socinski MA

更新日期：2010-05-01 00:00:00

abstract：:Bevacizumab is the first molecularly targeted agent associated with improved outcomes in combination with chemotherapy in previously untreated patients with non-small-cell lung cancer (NSCLC). The addition of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), to carboplatin and pacli...

journal_title：Clinical lung cancer

authors： Morgensztern D,Govindan R

更新日期：2008-03-01 00:00:00

abstract：:We present a rare case of recurrent multiple lesions of bronchial epithelial-myoepithelial carcinoma in a 74-year-old man treated with local resection. Two cellular types were found: epithelial cells and myoepithelial cells. The patient remains asymptomatic at 4-years of follow-up, supporting the fact that epithelial-...

journal_title：Clinical lung cancer

authors： Muslimani AA,Kundranda M,Jain S,Daw HA

更新日期：2007-05-01 00:00:00

abstract：BACKGROUND:Several studies have assessed the expression of programmed death-ligand 1 (PD-L1) in resected surgical specimens of non-small-cell lung cancer (NSCLC). However, the expression of PD-L1 in smaller biopsy samples of advanced NSCLC has not been reported. PATIENTS AND METHODS:A total of 79 patients with NSCLC a...

journal_title：Clinical lung cancer

authors： Kitazono S,Fujiwara Y,Tsuta K,Utsumi H,Kanda S,Horinouchi H,Nokihara H,Yamamoto N,Sasada S,Watanabe S,Asamura H,Tamura T,Ohe Y

更新日期：2015-09-01 00:00:00

abstract：INTRODUCTION:A recent review of phase I trials suggests that participation in these trials can be associated with clinical benefit and the rate of drug-related deaths is low. We conducted an analysis of the Cancer Therapy Evaluation Program (CTEP)-sponsored phase I trials to assess the outcomes of lung cancer patients ...

journal_title：Clinical lung cancer

authors： Gadgeel SM,Ivy P,Chen W,Mauer J,Smith D,Lorusso P

更新日期：2011-07-01 00:00:00

abstract：BACKGROUND:We investigated the effect of downstaging on OS in LD-SCLC patients treated with first-line treatment. PATIENTS AND METHODS:We retrospectively reviewed 210 LD-SCLC patients who were treated with first-line treatment at Seoul National University Hospital between April 1999 and November 2012. Compared with in...

journal_title：Clinical lung cancer

authors： Go SI,Keam B,Kim TM,Lee SH,Kim DW,Kim HJ,Wu HG,Chung DH,Heo DS

更新日期：2014-03-01 00:00:00

abstract：BACKGROUND:While lepidic-predominant lung adenocarcinomas are known to have better outcomes than similarly sized solid tumors, the impact of smaller noninvasive foci within predominantly solid tumors is less clearly characterized. We tested the hypothesis that lung adenocarcinomas with even a small ground-glass opacity...

journal_title：Clinical lung cancer

authors： Berry MF,Gao R,Kunder CA,Backhus L,Khuong A,Kadoch M,Leung A,Shrager J

更新日期：2018-01-01 00:00:00

abstract：:Systemic chemotherapy results in modest improvements in survival and quality of life for patients with advanced-stage non-small-cell lung cancer (NSCLC). Administration of a platinum compound in combination with a taxane (paclitaxel or docetaxel), gemcitabine, vinorelbine, or irinotecan is considered optimal first-lin...

journal_title：Clinical lung cancer

authors： Ramalingam S

更新日期：2005-12-01 00:00:00

abstract：:This phase I/II study was conducted to evaluate the safety and efficacy of tirapazamine in combination with cisplatin and vinorelbine for patients with advanced-stage IIIB/IV chemonaive non-small-cell lung cancer. Seventy patients with a Karnofsky performance status of > or = 60% were included. In the phase I part of ...

journal_title：Clinical lung cancer

authors： Gatineau M,Rixe O,Chevalier TL

更新日期：2005-03-01 00:00:00

abstract：:Antisense oligonucleotides (ASONs) are one of the new classes of molecularly targeted agents that have transitioned from the laboratory into clinical trials. Rational drug design has resulted in agents directed against a number of important cellular targets, including the mRNA of bcl-2, protein kinase (PK) C-alpha, PK...

journal_title：Clinical lung cancer

authors： Davies AM,Gandara DR,Lara PN Jr,Mack PC,Lau DH,Gumerlock PH

更新日期：2003-01-01 00:00:00

abstract：:Lung cancer is the leading cause of cancer deaths worldwide, with the majority of patients presenting with advanced disease. Despite the introduction of newer therapeutic agents and modest survival improvement, the overall prognosis for these patients is poor. The goals of therapy should therefore include improvement ...

journal_title：Clinical lung cancer

authors： Plunkett TA,Chrystal KF,Harper PG

更新日期：2003-07-01 00:00:00

abstract：BACKGROUND:The safety and efficacy of platinum-based combination chemotherapy for elderly patients with advanced non-small-cell lung cancer (NSCLC) remains unclear. We conducted phase I and phase II trials of a combination of vinorelbine and carboplatin for patients ≥75 years of age and with advanced NSCLC. PATIENTS A...

journal_title：Clinical lung cancer

authors： Takatani H,Nakamura Y,Nagashima S,Soda H,Kinoshita A,Fukuda M,Fukuda M,Soejima Y,Kasai T,Nakatomi K,Iida T,Oka M,Tsukamoto K,Kohno S

更新日期：2012-09-01 00:00:00

abstract：INTRODUCTION:Small-cell lung cancer (SCLC) is a highly vascularized tumor. ASA404 is a tumor vascular disrupting agent. This is the first trial to report the effects of combining chemotherapy with ASA404 in SCLC. METHODS:Patients with untreated metastatic SCLC were treated with carboplatin (area under curve, 6) plus p...

journal_title：Clinical lung cancer

authors： Früh M,Cathomas R,Siano M,Tscherry G,Zippelius A,Mamot C,Erdmann A,Krasniqi F,Rauch D,Simcock M,Küttel E,Fustier P,Pless M,Swiss Group for Clinical Cancer Research.

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:ROS1 gene fusions cause several cancers by constitutively activating the ROS1 tyrosine kinase receptor. ROS1-targeted inhibitor therapy improves survival in the approximately 1% to 2% of patients with lung adenocarcinoma with ROS1 gene fusions. Although fluorescence in situ hybridization (FISH) is the standa...

journal_title：Clinical lung cancer

authors： Boyle TA,Masago K,Ellison KE,Yatabe Y,Hirsch FR

更新日期：2015-03-01 00:00:00

abstract：BACKGROUND:Patients with multiple primary lung cancers increasingly receive multiple courses of stereotactic body radiotherapy (SBRT). We aimed to clarify the efficacy and safety of such treatments. PATIENTS AND METHODS:We reviewed a prospective lung SBRT database of patients treated for stage I non-small-cell lung ca...

journal_title：Clinical lung cancer

authors： Nikitas J,DeWees T,Rehman S,Abraham C,Bradley J,Robinson C,Roach M

更新日期：2019-03-01 00:00:00

abstract：BACKGROUND:In the present study we aimed to investigate whether the predominance of the lepidic component in tumors was associated with the outcome of postoperative adjuvant chemotherapy for stage I lung adenocarcinoma. PATIENTS AND METHODS:Charts for patients with pathological stage I lung adenocarcinoma were retrosp...

journal_title：Clinical lung cancer

authors： Sasada S,Miyata Y,Mimae T,Tsutani Y,Mimura T,Okada M

更新日期：2016-09-01 00:00:00

abstract：:Randomized clinical trials (RCTs) of concurrent epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) plus chemotherapy for unselected patients with advanced non-small-cell lung cancer (NSCLC) produced negative results. Intercalated administration could avoid the reduction of chemotherapy activity du...

journal_title：Clinical lung cancer

authors： La Salvia A,Rossi A,Galetta D,Gobbini E,De Luca E,Novello S,Di Maio M

更新日期：2017-01-01 00:00:00

abstract：:Viruses capable of inducing lysis of malignant cells through their replication process are known as "oncolytic" viruses. Clinical trials in oncology have been performed with oncolytic viruses for nearly fifty years. Both systemic and intratumoral routes of administration have been explored. Toxicity has generally been...

journal_title：Clinical lung cancer

authors： Nemunaitis JJ

更新日期：1999-08-01 00:00:00

abstract：UNLABELLED:Efficacy of first-line gefitinib for elderly epidermal growth factor receptor mutated patients with lung adenocarcinoma is uncertain. This study was aimed to investigate efficacy of gefitinib for such population. The primary endpoint was response rate (RR) and at least 12 cases were needed. Overall RR was 59...

journal_title：Clinical lung cancer

authors： Asami K,Koizumi T,Hirai K,Ameshima S,Tsukadaira A,Morozumi N,Morikawa A,Atagi S,Kawahara M

更新日期：2011-11-01 00:00:00

abstract：:This clinical trial summary provides the background and rationale for a randomized trial examining the benefits of pemetrexed/ cisplatin chemotherapy combined with radiation followed by consolidation pemetrexed in patients with unresectable stage IIIA/B non-small-cell lung cancer. The rationale for the selection of th...

journal_title：Clinical lung cancer

authors： Vokes EE,Senan S,Treat JA,Iscoe NA

更新日期：2009-05-01 00:00:00

abstract：OBJECTIVE:The objective of this study is to externally validate the 8th Edition of the Tumor, Node, and Metastasis staging system and its updated T descriptors in patients with non-small cell lung cancer with N3 disease. METHODS:Data were extracted from the Surveillance, Epidemiology, and End Results database. Chi-squ...

journal_title：Clinical lung cancer

authors： Shin JY,Yoon JK,Marwaha G

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:Thoracic radiotherapy (TRT) with concurrent chemotherapy is standard for limited-stage small-cell lung cancer (LS-SCLC). However, the optimal dosing and fractionation remain unclear. The National Comprehensive Cancer Network guidelines have recommended either 45 Gy delivered twice daily (BID) or 60 to 70 Gy ...

journal_title：Clinical lung cancer

authors： Farrell MJ,Yahya JB,Degnin C,Chen Y,Holland JM,Henderson MA,Jaboin JJ,Harkenrider MM,Thomas CR Jr,Mitin T

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Serum tumor markers are considered a negative prognostic factor in early-stages NSCLC but its role in advanced disease is controversial. The aim of this study is to analyze the prognostic value of tumor markers in advanced NSCLC. PATIENTS AND METHODS:Two hundred and seventy seven patients diagnosed in our i...

journal_title：Clinical lung cancer

authors： Cedrés S,Nuñez I,Longo M,Martinez P,Checa E,Torrejón D,Felip E

更新日期：2011-05-01 00:00:00

abstract：INTRODUCTION:We examined the effect of access to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy on survival for Asian female (AF) EGFR mutation-enriched patients with advanced lung adenocarcinoma. MATERIALS AND METHODS:We used the Surveillance Epidemiology and End Results database to s...

journal_title：Clinical lung cancer

authors： Becker DJ,Wisnivesky JP,Grossbard ML,Chachoua A,Camidge DR,Levy BP

更新日期：2017-01-01 00:00:00

abstract：:The ability to reliably distinguish synchronous primary non-small-cell lung cancer (NSCLC) from intrapulmonary metastatic spread affects staging and treatment decisions in resected NSCLC. Adjuvant therapy for early-stage NSCLC is complicated and recommendations are primarily based on older data from trials that used n...

journal_title：Clinical lung cancer

authors： Klempner SJ,Ou SH,Costa DB,VanderLaan PA,Sanford EM,Schrock A,Gay L,Ali SM,Miller VA

更新日期：2015-09-01 00:00:00

abstract：:Vascular endothelial growth factor (VEGF) is regulated by the hypoxia-inducible factor 1 (HIF1) pathway and is implicated in tumor progression and patient survival in many types of cancer. Insulin-like growth factor-binding protein 3 (IGFBP3) is also regulated by HIF1 but works in a completely different manner by modu...

journal_title：Clinical lung cancer

authors： Gharib TG,Chen G,Huang CC,Misek DE,Iannettoni MD,Hanash SM,Orringer MB,Beer DG

更新日期：2004-03-01 00:00:00

abstract：:The therapeutic options for patients with advanced non-small-cell lung cancer (NSCLC) are palliative. Therefore, the quality of life in oncology is considered as an endpoint in clinical trials, and several scales have been accepted for its measurement in parallel with other clinical determinations. However, its use in...

journal_title：Clinical lung cancer

authors： Camps C,del Pozo N,Blasco A,Blasco P,Sirera R

更新日期：2009-03-01 00:00:00

abstract：INTRODUCTION:Real-world data on current treatment practices for non-small-cell lung cancer (NSCLC) are needed to understand the place in therapy and potential economic impact of newer therapies. PATIENTS AND METHODS:This retrospective cohort study identified patients ≥ 65 years old in the Surveillance, Epidemiology, a...

journal_title：Clinical lung cancer

authors： Arunachalam A,Li H,Bittoni MA,Camacho R,Cao X,Zhong Y,Lubiniecki GM,Carbone DP

更新日期：2018-09-01 00:00:00

abstract：:The Lung Cancer Disease Site Group (DSG) of the Cancer Care Ontario Practice Guidelines Initiative first met in January of 1994. Included in the membership were three pathologists who, with the other members of the DSG, felt that a useful contribution to the work of the group would be a recommendation on standardized ...

journal_title：Clinical lung cancer

authors： Chamberlain DW,Wenckebach GF,Alexander F,Fraser RS,Kolin A,Newman T

更新日期：2000-05-01 00:00:00

abstract：BACKGROUND:There are few reports of treatment and outcome for patients with metachronous or synchronous lung and gastric cancers. To evaluate them, we conducted a retrospective study. PATIENTS AND METHODS:The medical records of patients with lung cancer who previously or simultaneously had gastric cancer seen in our d...

journal_title：Clinical lung cancer

authors： Kurishima K,Satoh H,Kagohashi K,Homma S,Nakayama H,Ohara G,Ishikawa H,Hizawa N

更新日期：2009-11-01 00:00:00